Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001861910 | SCV002282164 | uncertain significance | not provided | 2021-08-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004025162 | SCV002755116 | uncertain significance | not specified | 2022-02-02 | criteria provided, single submitter | clinical testing | The p.E1313K variant (also known as c.3937G>A), located in coding exon 36 of the IKBKAP gene, results from a G to A substitution at nucleotide position 3937. The glutamic acid at codon 1313 is replaced by lysine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000693675 | SCV001452809 | uncertain significance | Familial dysautonomia | 2020-09-16 | no assertion criteria provided | clinical testing |